April 26, 2016 - ST. HELIER, Jersey--(BUSINESS WIRE)--Physicians at more than 360 cancer treatment centers in the U.S. have been certified to prescribe Novocure’s (NASDAQ:NVCR) Optune to newly diagnosed and recurrent glioblastoma (GBM) patients. Physicians at an additional 140 medical institutions throughout the world also can prescribe Optune to GBM patients. Optune is a medical device used to deliver Tumor Treating Fields to disrupt cancer cell division and cause cancer cell death.
Physicians must be trained by Novocure to prescribe Optune therapy. Since FDA approval of Optune plus temozolomide for the treatment of newly diagnosed GBM in October 2015 based on the superior progression free and overall survival demonstrated in the EF-14 phase 3 pivotal clinical trial, physicians at more than 140 U.S. cancer treatment centers have been certified. An estimated 12,500 people are diagnosed with GBM or tumors that typically progress to GBM in the United States each year.
“More and more physicians are learning about Optune and the benefits it can offer GBM patients,” said Pritesh Shah, Novocure’s Senior Vice President, Americas. “We are committed to raising awareness of the therapy and making it readily available to the patients who need it.”
Ad Statistics
Times Displayed: 22687
Times Visited: 478 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Recently certified centers include Ochsner Medical Center, Premier Health – Miami Valley Hospital/Dayton Physicians, Rocky Mountain Oncology Center, Tulane University Department of Neurosurgery, the University of Tennessee Medical Center Cancer Institute, and Vanderbilt-Ingram Cancer Center.
"Optune enables us to offer GBM patients a treatment option that can extend patients’ lives while maintaining their quality of life,” said Dr. Marcus L. Ware, Medical Director for Neurosurgical Oncology at Ochsner Medical Center.
About Novocure
Novocure is a commercial-stage oncology company developing a novel, proprietary therapy called Tumor Treating Fields, or TTFields, for the treatment of solid tumor cancers. Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the company has offices in Germany, Switzerland and Japan, and a research center in Haifa, Israel. For additional information about the company, please visit www.novocure.com or follow us at www.twitter.com/novocure.
Approved Indications
In the United States, Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM).
